The Institute of Clinical Research (The ICR) board is comprised of up to 12 Board Director volunteers from Pharma, Biotech, CRO, Academia, Vendors, who govern the Institute according to the Articles of Memorandum

Karen Roy started her career as a clinical research associate at Chiltern International, joining The ICR Board from 2001 to 2006 when she headed the Clinical Development department in UK, Scandinavia and Central and Eastern Europe. Karen also ran EDC Solutions, a group supporting EDC implementation at Investigator sites. She then moved to Phlexglobal to focus on trial master files at Phlexglobal, including founding the TMF Reference Model. Karen is now consulting and passionate about the UK being one of the best places for Clinical Research and has therefore come full circle to Chair the ICR Board in support of this quest.

Dr Sally-Ann McDowell has worked in Clinical Research for almost 30 years. She has worked for large and mid size CROs in positions ranging from Data Co-ordinator, Biometrics Project Manager, Clinical Project Manager, Director of Project Management, Therapeutic Area Lead and is currently a Senior Clinical Development Strategy Director. She has global experience in many different therapeutic areas, including CNS, Neurology and Oncology. Sally-Ann has been a member of ICR for many years and was involved in the Project Management Special Interest Group and helped organise the ICR PM Forum in 2022. She is currently a Board member of ICR as well as being a STEM Ambassador.
Fiona Wallace, has worked in global CRO and pharma for over 20 years, spanning many countries and Phase I – IV studies such as oncology, ophthalmology, erectile dysfunction and rheumatoid arthritis. She specialises in developing high value retention learning solutions by utilising her breadth of experience in project and CRA management, global clinical regulatory training, inspection readiness management and provision of client solutions to improve staff retention and engagement. Many clinical researchers face the challenge of how to ensure their clinical trials comply with GCP & regulations: Fiona is determined to help them do so with patient safety and data reliability at the forefront.
Dr Tina Barton is an experienced drug development specialist with a broad knowledge within health care. She has held Senior Management operational roles in large global through mid-size to small emerging drug development organisations, providing leadership in trial delivery, managing teams and training for the future. As a past Chair of The ICR and Board Member (2000 – 2007) Tina’s commitment to The ICR led to her re-joining the Board in 2021. With her continued passion for sharing knowledge, raising standards and developing professionals, she develops and leads The ICR training initiatives.

Dr Jane Bentley Jane has over 35 years Oncology drug development experience in the pharmaceutical industry including Executive Leadership, project and portfolio management in Oncology and haematology drug development. She holds a BSc in Pharmacology, a PhD in Toxicology from University of London and an MBA in International Health Care management. Jane is a currently serving her second term on the ICR board (1998-2004, 2014 to present) and supports the ICR with regard to financial oversight and also in developing our links with other professional organisations involved in clinical research, including links with academia and the NHS to provide a voice for Clinical research in the UK

Viv Page is an experienced clinical research professional with almost 30 years of large pharma and CRO experience spanning a variety of operational and commercial roles, across a wide range of therapeutic areas. Viv has been a member of ICR for many years and recently re-joined the board in January 2024 to help drive the re-establishment of  ICR as the foremost UK organisation for clinical researchers.